Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Clinical Comparison of the Endeavor [zotarolimus] and the Cypher [sirolimus] Coronary Stents in Non-Selected Angina Pectoris Patients

Next Previous
Trial Profile

Randomized Clinical Comparison of the Endeavor [zotarolimus] and the Cypher [sirolimus] Coronary Stents in Non-Selected Angina Pectoris Patients

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms SORT-OUT-III

Most Recent Events

  • 06 Nov 2019 Results of subgroup analysis evaluating 10-year performance of sirolimus-eluting cypher stent and zotarolimus-eluting endeavor stent released in the American Journal of Cardiology
  • 31 Oct 2018 The SORT OUT III 10-year results will be reported at the ESC Congress. The subgroup analysis assessing 10 year outcomes in patients with or without diabeties has not yet been analyzed but will be ready for presentation at TCT as per trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
  • 25 Sep 2018 Trial design presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top